RC
LEGN icon

Renaissance Capital’s Legend Biotech LEGN Stock Holding History

Renaissance Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,300
Closed -$882K – 81
2023
Q1 		$882K Sell
18,300
-1,958
-10% -$95.8K 0.65% 42
2022
Q4 		$1.01M Sell
20,258
-60
-0.3% -$2.91K 0.79% 38
2022
Q3 		$829K Buy
20,318
+9,155
+82% +$430K 0.53% 49
2022
Q2 		$614K Buy
11,163
+3,647
+49% +$154K 0.33% 55
2022
Q1 		$273K Sell
7,516
-1,979
-21% -$78.2K 0.12% 92
2021
Q4 		$443K Buy
+9,495
New +$482K 0.11% 97

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Renaissance Capital's LEGN Position: Q2 2023 in Review

Renaissance Capital sold out of Legend Biotech (LEGN) in Q2 2023, closing a stake of 18,300 shares — an estimated $882K sold.

Renaissance Capital first reported a position in LEGN in Q4 2021 and held it in 6 quarters. The position peaked at $1.01M in Q4 2022. 194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

  • Renaissance Capital reported no remaining Legend Biotech position as of Q2 2023 after selling out during the quarter.
  • Renaissance Capital sold 18,300 Legend Biotech shares in Q2 2023, an estimated $882K.
  • Renaissance Capital first reported a position in Legend Biotech in Q4 2021 and held it in 6 quarters.
  • Renaissance Capital's Legend Biotech position peaked at $1.01M in Q4 2022.
  • 194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.